Global Chronic Kidney Disease Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

ACE Inhibitors, B-Blockers, Calcium Channel Blockers, Diuretics, Erythropoiesis-Stimulating Agents (ESAs,) and Others

By Type of Treatment;

Drugs, Dialysis, Transplantation Of Kidneys, and Others

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By End User;

Hospitals & Clinics, Ambulatory Surgery Centres (ASCs), Dialysis Centers, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn838122008 Published Date: May, 2025 Updated Date: June, 2025

Introduction

Global Chronic Kidney Disease Therapeutics Market (USD Million), 2021 - 2031

Chronic Kidney Disease Therapeutics Market was valued at USD 5,187.63 million in the year 2024. The size of this market is expected to increase to USD 6,179.10 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 2.5%.


Global Chronic Kidney Disease Therapeutics Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 2.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)2.5 %
Market Size (2024)USD 5,187.63 Million
Market Size (2031)USD 6,179.10 Million
Market ConcentrationHigh
Report Pages301
5,187.63
2024
6,179.10
2031

Major Players

  • Amgen, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • AstraZeneca Plc
  • F. Hoffman La Roche Ltd.
  • Sanofi S.A.
  • Kissei Pharmaceutical Co. Ltd.
  • AbbVie, Inc.
  • GlaxoSmithKline Plc
  • Keryx Biopharmaceuticals, Inc.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Chronic Kidney Disease Therapeutics Market

Fragmented - Highly competitive market without dominant players


The Chronic Kidney Disease (CKD) Therapeutics Market is expanding due to the increasing incidence of kidney-related health issues. The consistent rise in cases is propelling the market forward, highlighting the urgent need for therapeutic innovations.

Emphasis on Early-Stage Management
Healthcare systems are placing greater emphasis on the early identification and treatment of chronic kidney disease. Nearly 30% of all treatment interventions now begin during the early stages of CKD, reflecting improved diagnostic capabilities and heightened medical vigilance. This proactive approach is supporting better clinical outcomes and reshaping therapeutic strategies.

Innovations Driving Treatment Efficacy
Ongoing research and development are fueling new drug discoveries aimed at slowing CKD progression. Currently, over 25% of pipeline therapies are focused on protective and disease-modifying agents. These advancements are enhancing treatment standards and expanding options available to patients, making innovation a key growth driver in this market.

Addressing Comorbid Conditions
Chronic kidney disease is commonly linked to other chronic ailments like hypertension and diabetes, requiring a holistic treatment approach. Around 40% of therapeutic plans now integrate care for related conditions, underscoring the need for comprehensive solutions. This has led to a rise in demand for combination therapies and collaborative care frameworks.

Supportive Ecosystem for Market Expansion
Government support and improved healthcare accessibility are creating favorable conditions for market growth. More than 35% of CKD patients currently receive care through publicly funded healthcare programs. This increasing accessibility is encouraging both innovation and wider therapeutic adoption, ensuring the market’s continued development.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Type of Treatment
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Global Chronic Kidney Disease Therapeutics Market
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Growing Global Aging Demographic
        2. Rising incidence of diabetes and hypertension
        3. Increasing awareness about CKD
      2. Restraints
        1. High treatment costs
        2. Limited healthcare infrastructure in certain regions
        3. Stringent regulatory approvals
        4. Adverse effects of certain medications
      3. Opportunities
        1. Growing demand for personalized medicine
        2. Expansion of online pharmacies
        3. Focus on preventive healthcare measures
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Chronic Kidney Disease Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)
      1. ACE Inhibitors
      2. B-Blockers
      3. Calcium Channel Blockers
      4. Diuretics
      5. Erythropoiesis-Stimulating Agents (ESAs)
      6. Others
    2. Global Chronic Kidney Disease Therapeutics Market, By Type Of Treatment, 2021 - 2031 (USD Million)
      1. Drugs
      2. Dialysis
      3. Transplantation Of Kidneys
      4. Others
    3. Global Chronic Kidney Disease Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacie
    4. Global Chronic Kidney Disease Therapeutics Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals & Clinics
      2. Ambulatory Surgery Centres (ASCs)
      3. Dialysis Centers
      4. Others
    5. Global Chronic Kidney Disease Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Amgen, Inc.
      2. Teva Pharmaceutical Industries Ltd.
      3. Pfizer, Inc.
      4. AstraZeneca Plc
      5. F. Hoffman La Roche Ltd.
      6. Sanofi S.A.
      7. Kissei Pharmaceutical Co. Ltd.
      8. AbbVie, Inc.
      9. GlaxoSmithKline Plc
      10. Keryx Biopharmaceuticals, Inc.
  7. Analyst Views
  8. Future Outlook of the Market